Preferentially Expressed Antigen in Melanoma (PRAME) Peptid
PRAME
Reaktivität: Säugetier
Wirt: Synthetic
BP, WB, IHC
-
- Target Alle PRAME Produkte
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Protein-Typ
- Synthetic
- Spezies
- Säugetier
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequenz
- AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
- Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of PRAME antibody,
Alternative Names: PRAME control peptide, PRAME antibody Blocking Peptide, Anti-PRAME Blocking Peptide, Preferentially Expressed Antigen In Melanoma Blocking Peptide, MAPE Blocking Peptide, OIP4 Blocking Peptide
-
-
- Applikationshinweise
- Optimal conditions should be determined by the investigator
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handhabung
- Avoid repeated freeze/thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20 °C long term.
-
- Target
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Synonyme
- PRAME Peptide, CT130 Peptide, MAPE Peptide, OIP-4 Peptide, OIP4 Peptide, 4930534P07Rik Peptide, preferentially expressed antigen in melanoma Peptide, PRAME Peptide, Prame Peptide
- Hintergrund
- PRAME functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. PRAME prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
- Molekulargewicht
- 56 kDa
-
Sie sind hier:
